Peppi Prasit

Dr. Prasit previously served as a Director at Tempest Therapeutics and the CEO of Inception Sciences. Prior to Inception, he was the founder and CSO of Amira Pharmaceuticals, which was acquired by Bristol-Myers Squibb. He has more than 20 years of experience in pharmaceutical research and management serving in various positions with Merck Frosst Canada and then Merck San Diego. During this time, he played a pivotal role in the discovery of multiple marketed drugs and is widely recognized for his accomplishments as a drug hunter.

Dr. Prasit received his B.Sc. from UCL, London University, and his Ph.D. from Victoria University of Wellington in New Zealand and was a postdoctoral fellow at Princeton University.